43 results
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
1 Jul 21
Celularity and Arthrex Enter into Exclusive Supply and Distribution Agreement for Multiple Commercial Products
5:07pm
States
FLORHAM PARK, NJ, and NAPLES, FL, July 01, 2021— Celularity Inc. (“Celularity”), a clinical-stage biotechnology company developing innovative cell … a variety of clinical conditions. We look forward to working closely with Arthrex to increase the availability of these innovative products in orthopedic
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
7 Sep 23
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
4:21pm
Significant Innovative Technology and Development Expertise Launching New Cellular Therapies
FLORHAM PARK, N.J., September 7, 2023 (GLOBE NEWSWIRE … expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need.
Throughout his career, Dr. Ling has made
425
CELU
Celularity Inc - Ordinary Shares
1 Jul 21
Business combination disclosure
5:09pm
. (“Celularity”), a clinical-stage biotechnology company developing innovative cell therapies and biomaterial products derived from the postpartum human … to increase the availability of these innovative products in orthopedic surgery and sports medicine, and to improve the lives of patients.”
Arthrex
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
29 Aug 23
Celularity Announces Multi-year Research Collaboration Services Agreement with Regeneron
9:15am
in innovative medicines.”
About Celularity
Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a biotechnology company leading the next … . In addition, Celularity develops, manufactures and commercializes innovative biomaterial products also derived from the postpartum placenta. Celularity believes
425
CELU
Celularity Inc - Ordinary Shares
7 Jul 21
Business combination disclosure
4:11pm
in Medicine Award for his innovative work in cellular therapy and the Golden Axon Award for his contributions and presidential leadership of SBMT … , Celularity is advancing innovative cellular therapeutics to treat a range of diseases, including neurologic diseases from brain cancer to stroke. In addition
8-K
EX-99.1
a1nzvocbv5si4 mlfi
16 Aug 21
Celularity Reports Second Quarter 2021 Financial Results
5:20pm
8-K
EX-99.1
hqif3wr0 r1pbxsu
22 Jul 21
Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update
4:13pm
8-K
EX-99.1
ttqqfqbeg7a2
31 Mar 22
Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
4:06pm
8-K
EX-99.1
d09s630ws
6 Apr 23
Celularity Inc. Announces $6 Million Registered Direct Offering
8:58pm
8-K
EX-99.1
4yn7s3x5ka9k7g4vgai8
28 Jul 23
Celularity Inc. Announces $3 Million Registered Direct Offering
4:27pm
8-K
EX-99.1
ogntnulntan53bypjeg
20 May 22
Celularity Inc. Announces $30 Million Private Placement
4:06pm
8-K
EX-99.1
epmwy0y3 zwxjs
28 Dec 21
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML
4:01pm
8-K
EX-99.1
khni82z0v
16 Feb 22
Other Events
8:31am
8-K
EX-99.1
eg2tauehws3p6g8o
12 Nov 21
Celularity Reports Third Quarter 2021 Financial Results and Corporate Update
4:19pm
8-K
EX-99.1
ggb8zz
18 Jan 22
Other Events
4:06pm
8-K
EX-99.1
r6yu3uciavudkpknt8
16 May 22
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:47pm
8-K
EX-99.1
6k33z42q2jn5pgcasn
27 Apr 23
Other Events
5:01pm
8-K
EX-99.1
i23jyv64 m9b4uuw
31 May 23
THE NEXT EVOLUTION IN CELLULAR MEDICINE Investor Presentation June 2023
5:08pm
8-K
EX-99.1
5b1e8w
10 Aug 22
Celularity Reports Second Quarter 2022 Financial Results and Corporate Update
12:00am
424B3
ckr5h b4c9yysre3
28 Dec 21
Prospectus supplement
4:05pm